Reston, VA (August 28, 2026)—New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
Summaries of the newly published research articles are provided below.
Dual-Threshold PET Contouring Helps Assess Neuroendocrine Tumors
Researchers developed a dual-threshold approach for measuring tumor volume on 68Ga-DOTATATE PET/CT, accounting for differences between liver and extrahepatic lesions. In 151 patients with advanced gastroenteropancreatic neuroendocrine neoplasms, higher total lesion volume was associated with shorter overall survival and time to treatment failure.
FAPI PET/CT Improves Detection of Ovarian Cancer Spread
A study of 200 patients with ovarian cancer compared 68Ga-FAPI-04 PET/CT with contrast-enhanced CT for detecting peritoneal carcinomatosis before surgery. Both imaging methods correlated with surgical assessments of tumor burden, while FAPI PET/CT showed greater sensitivity, particularly for disease in the upper abdomen and small bowel.
CD8-Targeted PET Tracks Immune Response in Lung Cancer
Researchers used 68Ga-NODAGA-SNA006 PET/CT to visualize CD8+ T cells in 14 patients with lung cancer. Advanced disease was associated with lower circulating CD8+ T cells and increased uptake in the spleen and bone marrow. During anti–PD-1 therapy, CD8+ T-cell distribution changed according to tumor PD-L1 expression.
Glypican-3 PET Shows Promise for Liver Cancer Imaging
A study of 14 patients with hepatocellular carcinoma evaluated 68GaGa-RAYZ-8009 PET/CT, a tracer targeting glypican-3, a protein commonly found in liver cancer. Most tumors showed tracer uptake, and uptake levels were strongly correlated with glypican-3 expression measured in tumor tissue.
Dual-Targeted Radiopharmaceutical Shows Promise in Advanced Cancers
Researchers conducted a first-in-human study of 177Lu-DOTA-FAPI-RGD (177Lu-LNC1009), designed to target both fibroblast activation protein and integrin αvβ3. Nine patients with advanced solid tumors received treatment, which was generally well tolerated. Tumor radiation doses were substantial, with partial responses in two patients and stable disease in six.
Visit the JNM website for the latest research, follow our Twitter and Facebook
